title: When tumor suppressor TGFβ meets the HER2 (ERBB2) oncogene.
abstract: Despite its tumor suppressive role in normal mammary epithelial cells, TGFβ has been reported to promote the migration, invasion and survival in breast cancer cells overexpressing the HER2 (ERBB2; neu) oncogene, and to accelerate the metastasis of neu-induced mammary tumors in mice. A clearer understanding of the molecular mechanisms underlying the crosstalk between TGFβ and HER2 has started to emerge. In recent studies reviewed here, the synergistic effect of TGFβ and HER2 on tumor progression has been shown to likely be a combined result of two distinct features: (1) loss of TGFβ's tumor suppressive effect through functional alterations in the anti-mitogenic effect of Smad-mediated transcription, and (2) gain of pro-survival and pro-migratory function through HER2-dependent mechanisms. In HER2-overexpressing breast cancer, this crosstalk results in increased cancer cell proliferation, survival and invasion, accelerated metastasis in animal models, and resistance to chemotherapy and HER2-targeted therapy. Thus, the transformed cellular context imparted by constitutively active HER2 signaling, as a consequence of HER2 gene amplification or overexpression, aborts the tumor suppressive role of TGFβ and facilitated the oncogenic role of this pathway. In turn, TGFβ potentiates oncogenic HER2 signaling by inducing shedding of the ERBB ligands and clustering of HER2 with integrins. Here we discuss recent studies examining Smad-dependent and -independent mechanisms of crosstalk between TGFβ and HER2. Therefore, blockade of TGFβ:HER2 crosstalk may suppress breast cancer progression and metastasis, and enhance the efficiency of conventional therapies in patients with HER2-overexpressing breast cancer.
authors: Division of Tumor Cell Biology, Department of Cancer Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
authors: Amy
authors: A
authors: Chow
authors: Carlos L
authors: CL
authors: Arteaga
authors: Shizhen Emily
authors: SE
authors: Wang
references: Cancer Cell. 2006 Sep;10(3):203-14
references: 16959612
references: Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3738-43
references: 15701700
references: J Biol Chem. 2004 Jun 4;279(23):24505-13
references: 15044465
references: Cancer Res. 2009 Jan 15;69(2):475-82
references: 19147560
references: Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11
references: 15158434
references: Cancer Cell. 2003 Jun;3(6):531-6
references: 12842082
references: Cell Res. 2004 Dec;14(6):497-506
references: 15625017
references: Cancer Res. 2010 Dec 1;70(23):9927-36
references: 21098707
references: Cell. 2000 Oct 13;103(2):295-309
references: 11057902
references: Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1257-62
references: 14739340
references: Oncogene. 1991 Jul;6(7):1189-94
references: 1713661
references: Nature. 2003 Oct 9;425(6958):577-84
references: 14534577
references: Oncologist. 1998;3(4):237-252
references: 10388110
references: Cancer Res. 2002 Aug 15;62(16):4690-5
references: 12183427
references: Cancer Biol Ther. 2011 May 1;11(9):793-800
references: 21307659
references: J Biol Chem. 2003 Nov 7;278(45):44377-84
references: 12947087
references: EMBO J. 1996 May 15;15(10):2452-67
references: 8665853
references: Science. 2004 Feb 6;303(5659):844-8
references: 14704432
references: Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
references: 11252954
references: Cancer Res. 2002 Jun 1;62(11):3151-8
references: 12036928
references: Cancer Res. 2002 Jul 15;62(14):4132-41
references: 12124352
references: Nat Genet. 2001 Oct;29(2):117-29
references: 11586292
references: J Clin Oncol. 2000 Sep 15;18(18):3230-9
references: 10986055
references: Cancer Res. 2006 Oct 1;66(19):9591-600
references: 17018616
references: Science. 1989 May 12;244(4905):707-12
references: 2470152
references: Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6809-14
references: 9618494
references: J Clin Oncol. 2002 Feb 1;20(3):719-26
references: 11821453
references: Am J Pathol. 2002 Jun;160(6):2081-93
references: 12057913
references: Cancer Res. 2002 Jan 15;62(2):497-505
references: 11809701
references: Nat Cell Biol. 2001 Sep;3(9):785-92
references: 11533657
references: Mol Cancer Res. 2010 Dec;8(12):1633-42
references: 21047769
references: Oncogene. 2010 Jun 10;29(23):3335-48
references: 20383197
references: Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9
references: 1350088
references: EMBO J. 1997 Apr 1;16(7):1647-55
references: 9130710
references: Semin Oncol. 1999 Aug;26(4 Suppl 12):78-83
references: 10482197
references: Mol Cell Biol. 2003 Dec;23(23):8691-703
references: 14612410
references: J Biol Chem. 1999 Mar 26;274(13):8865-74
references: 10085130
references: Clin Cancer Res. 2007 Feb 15;13(4):1198-207
references: 17317830
references: Oncogene. 1995 May 4;10(9):1813-21
references: 7538656
references: Cancer Cell. 2004 Aug;6(2):117-27
references: 15324695
references: N Engl J Med. 2002 Dec 19;347(25):1999-2009
references: 12490681
references: Mol Cell Biol. 2008 May;28(10):3162-76
references: 18332126
references: Oncogene. 2006 Jun 8;25(24):3408-23
references: 16186809
references: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8430-5
references: 12808151
references: Cell. 2003 May 2;113(3):301-14
references: 12732139
references: Mol Cell Biol. 2008 Sep;28(18):5605-20
references: 18625725
references: J Clin Oncol. 1999 Sep;17(9):2639-48
references: 10561337
references: J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7
references: 11752009
references: J Biol Chem. 2007 Feb 23;282(8):5661-9
references: 17204482
references: Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):937s-43s
references: 15701890